ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1366	National Cancer Institute	Html	en	Pruritus (PDQ®)–Health Professional Version	Expert-reviewed information summary about pruritus (itching of the skin) as a complication of cancer or its treatment. Approaches to the management and treatment of pruritus are discussed.	pruritus 0.960641 second-generation antihistamines 0.585479 skin type 0.575303 atopic dermatitis 0.673145 skin surface 0.599366 worst pruritus 0.717892 atopic dermatitis population 0.574946 severe non-dermatological pruritus 0.718081 skin lipids 0.573883 Acad Dermatol Venereol 0.589376 primary dermatitis 0.600506 significant skin breakdown 0.59383 blood flow 0.584198 allergic skin reactions 0.594569 patients 0.575543 Dermatol Venereol Leprol 0.585578 placebo-controlled study 0.5912 radiation therapy 0.686843 Int J Dermatol 0.586614 Pain Symptom Manage 0.63754 healthy skin 0.593613 dry skin 0.639653 neuropathic pruritus 0.745005 et al. 0.592668	skin cleansing 0.573636 treatment 0.596222 skin reactions 0.599238 Oncol Nurs Forum 0.699339 skin dermatitis 0.603221 Opioid-induced Pruritus 0.704011 skin 0.704869 uraemic pruritus 0.705232 PUBMED Abstract 0.858232 Altered skin integrity 0.588103 Skin care 0.624412 Acta Derm Venereol 0.596823 pruritus relief 0.700635 itch 0.57584 allergic contact dermatitis 0.578553 skin hydration 0.574125 Clin Exp Dermatol 0.593566 skin change 0.583853 aggravates dry skin 0.598514 chronic idiopathic urticaria 0.638535 cholestatic pruritus 0.69774 Dermatol Ther 0.606265 intractable pruritus 0.703673 chronic pruritus 0.736276	CLICK HERE
1396	National Cancer Institute	Html	en	Levels of Evidence for Adult and Pediatric Cancer Treatment Studies (PDQ®)–Health Professional Version	Information about how to weigh the strength of the evidence obtained in different kinds of cancer treatment studies.	study allocations 0.55994 stronger conclusions 0.590358 randomized studies 0.798135 strength 0.75642 evidence 0.657795 study allocation 0.562189 clinical trials 0.717908 randomized study designs 0.766704 small systematic errors 0.589877 case-control studies 0.668928 PDQ editorial boards 0.679562 randomized trial 0.636458 individual studies 0.60263 response rate 0.616842 case-only series 0.70041 study design 0.888134 observational study designs 0.736094 PDQ Adult Treatment 0.665736 nonconsecutive cases 0.672159 PDQ Adult Cancer 0.655778 therapeutic strategy 0.618175 tumor response rate 0.613151 consecutive series 0.605201 Treatment Editorial Board 0.756511	explicit prospective hypotheses 0.587622 internal-control study subjects 0.746476 internal comparison group 0.725592 patient selection 0.600103 different cut points 0.60745 nonblinded randomized study 0.746604 study designs 0.92108 case series 0.614267 clinical trial—to case 0.64839 study arms 0.543205 PDQ Pediatric Treatment 0.659091 statistically significant results 0.596562 PDQ Pediatric Cancer 0.649154 series experiences 0.541012 clinical experiences 0.670302 different expert panels 0.607615 overall strength 0.584647 definable population 0.605214 study results 0.54495 previously conducted studies 0.628589 Cancer Treatment Summaries 0.759718 clinical studies 0.588362 population-based studies 0.62839 subset analyses 0.608887	CLICK HERE
1467	National Cancer Institute	Html	en	Anal Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of anal cancer.	fewer anal cancer 0.530738 Anal Cancer Trial 0.634424 concurrent chemoradiation 0.404217 superior 5-year DFS 0.378744 chemotherapy 0.429335 epidermoid anal cancer 0.547504 anal canal 0.766504 clinical trials 0.392035 salvage chemoradiation therapy 0.390967 Int J Radiat 0.469454 anal cancer. 0.475149 Radiation Therapy Oncology 0.402396 nonanal cancer deaths 0.396823 Radiat Oncol Biol 0.605474 maintenance chemotherapy 0.418444 concurrent chemotherapy 0.390419 patients 0.377289 Natl Cancer Inst 0.384135 epidermoid carcinoma 0.399722 radiation therapy 0.654579 small anal cancers 0.512705 Semin Radiat Oncol 0.380575 et al. 0.386836 3-year progression-free survival 0.377529	maintenance chemotherapy vs 0.403961 abdominoperineal resection 0.383597 radiation boost 0.391451 5-year survival rate 0.437197 Standard salvage therapy 0.381272 anal carcinoma 0.641081 United Kingdom Co-ordinating 0.376629 Co-ordinating Committee 0.376634 Primary radiation therapy 0.406548 Cancer Research 0.387349 lower-dose radiation therapy 0.423308 cisplatin 0.411059 Abstract 0.428082 local control 0.379418 Clin Oncol 0.397813 Oncol Biol Phys 0.623359 cisplatin arm 0.407457 anal cancer 0.917755 optimal radiation dose 0.392447 randomized controlled trial 0.377687 UKCCCR Anal Cancer 0.490305 anal canal carcinoma 0.506155 induction chemotherapy 0.42421 squamous cell carcinoma 0.39993	CLICK HERE
1628	National Cancer Institute	Html	en	Urethral Cancer Treatment (PDQ®)–Patient Version	Urethral cancer occurs in men and women and can spread quickly to lymph nodes near the urethra. Find out about risk factors, symptoms, tests to diagnose, prognosis, staging, and treatment for urethral cancer.	cancer treatment 0.362333 entire urethra 0.306444 lymph node dissection 0.557244 tissue 0.317299 body 0.398643 PDQ cancer information 0.410389 clinical trial search 0.378188 white blood cells 0.310278 bladder cancer 0.308764 clinical trials 0.773033 nearby lymph nodes 0.630197 cancer information summary 0.370147 clinical trial 0.499273 breast cancer prevention 0.294123 prostate gland 0.293841 patients 0.324988 invasive bladder cancer 0.301679 treatment clinical trial 0.300741 NCI PDQ cancer 0.319347 radiation therapy 0.651339 Urethral Cancer Treatment 0.356944 Treatment Editorial Board 0.30592 urethral cancer 0.837946 recurrent urethral cancer 0.334114	General information 0.298754 treatment 0.543719 new cancer treatments 0.306575 NCI-supported cancer 0.322826 cancer cells 0.450964 proximal urethral cancer 0.41852 urethral cancer spreads 0.344537 Cancer Information Service 0.306473 laser surgery 0.302658 patient 0.295185 treatment clinical trials 0.339398 anterior exenteration 0.294741 National Cancer Institute 0.373731 transurethral resection 0.314195 new treatment 0.34401 distal urethral cancer 0.388721 external radiation therapy 0.308401 cancer research process 0.298298 cancer clinical trials 0.402611 cancer information summaries 0.303961 comprehensive cancer information 0.304414 internal radiation therapy 0.302856 cancer 0.977674 standard treatment 0.307427	CLICK HERE
1814	National Cancer Institute	Html	es	Tratamiento del cáncer de esófago (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de esófago.	potentially operable carcinoma 0.227364 Compton CC 0.235729 gastric cardia carcinomas 0.224835 oesophageal cancer 0.276104 M0 TX 0.378744 largo plazo 0.224774 7th ed 0.235623 Oesophageal Cancer Followed 0.223828 Symptomatic gastroesophageal reflux 0.225069 ecografía endoscópica 0.322801 Estados Unidos 0.43962 mortalidad perioperatoria 0.229531 Natl Cancer Inst 0.232717 estadificación tnm 0.223626 La incidencia 0.230541 estadio iv 0.258573 M0 T2 0.809899 tumor.ampliar cáncer 0.321047 M0 T1 0.972287 Lerut A 0.228355 M0 T3 0.670603 estadio ib 0.273395 estadio ia 0.270617 células escamosas versus 0.290657 Van Cutsem E 0.252346	Estadio Grado Localización 0.256738 mucosa esofágica distal 0.27828 tumor.ampliar adenocarcinoma 0.241411 Cancer Staging Manual 0.279268 iia 1-x superior 0.228 Thorac Cardiovasc Surg 0.318859 estadio iiia 0.354448 PDQ Tratamiento 0.239147 New York 0.233171 invasive surgical staging 0.223534 estadio iiic 0.343305 estadio iia 0.319628 Cancer treatment 0.223659 Clin Oncol 0.262378 medio t2–3 0.237546 Byrd DR 0.234186 M1 TX 0.23325 American Joint Committee 0.2654 Thorac Surg 0.250251 M0 Tis 0.325056 positron emission tomography 0.377883 Am Coll Surg 0.230102 M0 T4a 0.550107 AJCC Cancer Staging 0.282666	CLICK HERE
1835	National Cancer Institute	Html	es	Tratamiento del mesotelioma maligno (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer del mesiotelioma maligno.	advanced malignant 0.116955 Cancer Res Clin 0.143881 unresectable malignant mesothelioma 0.113438 malignant mesothelioma previously 0.112719 Lung Cancer Study 0.118498 Leukemia Group 0.124194 Venkatraman E 0.115582 therapy with induction 0.114339 Antman KH 0.111559 Vogelzang NJ 0.12467 systemic chemotherapy 0.119496 patients with mesothelioma 0.113972 Thorac Oncol 0.117632 malignant mesothelioma 0.548307 with induction chemotherapy 0.120652 cisplatino versus 0.116229 Res Clin Oncol 0.141606 mesotelioma sarcomatoide 0.113237 intraperitoneal chemotherapy as 0.127133 patients with 0.17944 Union Against Cancer 0.114155 chemotherapy followed 0.119996 cisplatin-based intraperitoneal chemotherapy 0.127819 Lung Cancer 0.119323 multimodality approach 0.111112	PDQ Síndromes cardiopulmonares 0.116256 pleural maligno difuso 0.117211 Rusch VW 0.116274 patients with malignant 0.151958 National Cancer Institute 0.112603 induction chemotherapy followed 0.11661 Thorac Cardiovasc Surg 0.13604 Trimodality therapy with 0.114339 malignant pleural mesothelioma 0.977908 malignant peritoneal mesothelioma 0.154368 Clin Oncol 0.739133 extrapleural pneumonectomy 0.187603 diagnosed pleural mesothelioma 0.118912 DeCamp M 0.110451 pleural mesothelioma using 0.118896 cisplatino pemetrexed 0.111439 chemotherapy as treatment 0.13551 treated patients with 0.113408 advanced malignant mesothelioma 0.112494 Mentzer SJ 0.110243 European Organization 0.127591 Thorac Surg 0.114739 diffuse malignant mesothelioma 0.138575 pleural malignant 0.119345	CLICK HERE
1964	National Cancer Institute	Html	es	Tratamiento del cáncer de uretra (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de uretra.	uretra distal 0.983772 siguientes procedimientos 0.582434 siguientes elementos 0.524145 siguientes aspectos 0.522333 proximal.ampliar anatomía 0.514787 enfermedad.ampliar ureteroscopía 0.522025 Physician Data Query 0.500221 VPH tipo 0.523805 túbulos renales 0.527052 siguientes tipos 0.512788	libre uso 0.498555 media pulgada 0.51317 rayos x 0.553518 sistema urinario masculino 0.542122 pequeño rulo 0.511879 Cancer Institute 0.497836 siguientes riesgos 0.497881 realidad células 0.521213 pelvis renal 0.642604 Institutos Nacionales 0.50085	CLICK HERE
3529	National Cancer Institute	Html	es	Cáncer de próstata, nutrición y suplementos alimentarios (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de la nutrición y los suplementos alimentarios para disminuir el riesgo de presentar cáncer de próstata o como tratamiento del mismo.	siglo xvii 0.306907 diario polyphenon 0.307426 productos alimenticios 0.340812 causa efectos 0.30879 té oolong 0.331426 calcio lácteo 0.324026 siguientes alimentos 0.308786 beneficios escasos 0.305604 productos lácteos 0.477796 fase ii 0.324128 vitamina d 0.307135 pacientes dosis 0.311906 futuros estudios 0.316382 hormonas masculinas 0.314232 hormonas sexuales masculinas 0.313427 llamada pcm 0.309543 posibles efectos 0.310927 insuficiencia hepática aguda 0.310772 ml /taza 0.306352 Estados Unidos 0.987475 menores concentraciones 0.310564 epigalocatequina gegc 0.310451 menor riesgo 0.310031 efectos secundarios dañinos 0.344646 siguientes observaciones 0.305279	efectos protectores 0.321928 histonas desacetilasas 0.307206 punica granatum l 0.307286 inyectó gegc 0.309986 cuerpo almacena calcio 0.328293 United States Preventive 0.312326 hiperplasia prostática benigna 0.310399 modelos animales 0.370702 vía oral 0.33411 cabo investigaciones 0.30894 lesiones tipo npi 0.310391 molestias estomacales 0.315997 ¿El calcio 0.323919 menor multiplicación 0.328691 suficientes pruebas 0.30615 partes distantes 0.305904 Services Task Force 0.311967 principales fuentes 0.306362 radicales libres 0.306952 corto plazo 0.30542 cabo estudios 0.372156 posibles beneficios 0.305916 Camellia sinensis 0.307372 ¿El té 0.326561	CLICK HERE
3931	National Cancer Institute	Html	en	Learning to Relax	Relaxation and imagery exercises to help reduce pain and stress from cancer and its treatment.	shoulders 0.453305 pleasant feeling 0.651461 pain signals 0.63782 ball heals 0.631444 knees 0.454376 couch 0.451674 rhythmic breathing 0.676847 body 0.56267 setting 0.457548 comfortable position 0.657532 major muscle groups 0.848895 muscles 0.673084 imagery exercises 0.661225 peaceful scene 0.643243 energy 0.537384 chest 0.581297 tension 0.507605 small pillow 0.658559 helpful relaxation skills 0.912366 comfortable chair 0.657031 quiet place 0.669508 exercises online 0.668318 mind wanders 0.665368 buttocks 0.461761 deep breathing 0.687493	relaxes 0.458398 activity 0.488323 Breathe 0.656053 following exercise 0.62127 distractions 0.457474 example 0.497694 head 0.451046 ball 0.667435 Close your eyes 0.888333 Begin 0.451378 class 0.454094 deep breath 0.879652 relaxation DVD 0.697919 CD 0.454044 pain 0.726885 familiar music 0.661667 open your eyes 0.646831 severe pain 0.642137 people 0.511709 way 0.451018 slow breathing 0.70237 relaxing pace 0.673964 discomfort 0.452497 cancer 0.45461	CLICK HERE
16650	National Cancer Institute	Html	en	IOTF Mentors: Track 1 and Track 2	While at FDA, fellows are assigned a mentor who is a senior member of FDA scientific review staff. Learn more about mentors for Tracks 1 and 2.	drug product review 0.763531 Clinical Evaluation 0.730644 Advisory Committee meetings 0.730511 Hematology Oncology Toxicology 0.80093 Oncology Drug Regulation 0.827479 FDA Office 0.747931 FDA scientific review 0.854344 pharmaceutical manufacturers 0.733082 Oncology Products Office 0.814936 research 0.757558 Biologics Evaluation 0.740263 clinical pharmacologists 0.727898 Regulatory training 0.800464 investigational new drugs 0.747261 Clinical Oncology Reviewer 0.848942 continued clinical activities 0.77796 clinical trials 0.899868 trial design 0.727681 Attend professional meetings 0.742121 multiple datasets/clinical trials 0.738642 Investigational New Drug 0.775585 single clinical trial 0.788427 new drug applications 0.86424 clinical outcome 0.778656 NDA review process 0.758002	clinical pharmacology 0.838285 oncologic product development 0.729454 Innovative clinical trial 0.816069 internal FDA meetings 0.79892 FDA 0.887939 Biologic License Applications 0.733421 clinical oncologists 0.919688 Innovative Quantitative Methods 0.737333 new drugs 0.799324 Drug Evaluation 0.758545 new computational methods 0.750069 Pivotal Trial Data 0.777331 NIH clinical center 0.785514 phase clinical oncology 0.913342 clinical oncology trials 0.923 oncology products 0.879348 oncology product development 0.777566 clinical trials design 0.798466 late phase trials 0.755358 gene therapies 0.850877 clinical trial data 0.865175 Oncology Drug Products 0.81665 data analysis methods 0.780168 research project 0.749995	CLICK HERE